Collaborative Research Plan Sample Clauses

Collaborative Research Plan. A Collaborative Research Plan which sets forth GI’s and MetaMorphix’s specific activities under the Collaborative Research and coordinates the Gi’s and MetaMorphix’s respective activities under the Collaborative Research, is attached hereto as Schedule 3.4.2. With respect to coordination of the GI’s and MetaMorphix’s activities under the Collaborative Research, the Collaborative Research Plan shall be reviewed each calendar quarter by the RMC. The Parties shall endeavor to carry out their portion of the Collaborative Research Plan consistent with the descriptions of Schedule 3.4.2.
Sample 1
AutoNDA by SimpleDocs
Collaborative Research Plan. 1.1 Each of the Parties agrees to use its reasonable efforts to conduct research and development lo evaluate and frn1her develop for commercial applications, certain targeted therapeutics identified or otherwise characterized hereunder ultimately with the goal of commercial applications, with the assistance, cooperation and guidance of a dedicated team. The Project shall be conducted in accordance with the statement of work attached hereto and made a part hereof as Exhibit A (the “Statement of Work”). The Statement of Work outlines the proposed phases of the research as well as proposed timelines and funding of research to be unde11aken by the Institution on behalf of the Parties. In undertaking the Project, the Parties shall use their respective reasonable efforts to execute the Project in accordance with prevailing high professional standards and will use reasonable efforts to produce consistently high levels of accuracy and expertise and to meet timetables associated with the applicable Statement of Work. The Parties shall use their respective reasonable efforts to perform the Project in accordance witl1 federal, state and local laws and regulations applicable to the research, as appropriate, including, without limitation, academic standards and all laws and regulations that apply to such standards and applicable ethical standards as well as in accordance with U.S. Food and Drug Administration Good Laboratory Practice regulatory standards. For the avoidance of doubt, any clinical portions of the Project will be perforu1ed in compliance with Good Clinical Practice as set forth in Title 21 of the U.S. Code of Federal Regulations (“C.F.R.”) and all applicable local, state and federal Laws governing the perforu1ance of clinical investigations including but not limited to the Federal Food, Drug, and Cosmetic Act as applicable. Neither Party guarantees that any patent rights shall result from the Project, that the scope of any patent rights that may result shall cover either Party’s commercial interest or that any such patent rights shall be free of dominance by other patents, including patents based upon inventions made by other inventors employed by either Party independently of their collaboration in this Project. Neither Party provides any warranty as to the commercial or scientific value of any results achieved under this Agreement. Scythian does not warrant the successful grant of its patent application upon which this research Project is based, any non...
Sample 1
Collaborative Research Plan. General Overview. Ercole and AVI will identify and develop Splicing Modulators that modulate the splicing of Ercole-AVI Exclusive Targets and AVI Exclusive Targets, as more specifically described in the Research Plan. All data and information generated as a result of either Party’s identification of Splicing Modulators that modulate the splicing of Ercole-AVI Exclusive Targets shall be owned by Ercole. All data and information generated as a result of either Party’s identification of Splicing Modulators that modulate the splicing of AVI Exclusive Targets shall be owned by AVI. Ownership of Splicing Modulators and any resultant patents will be determined pursuant to Section 4.1(d).
Sample 1
Collaborative Research Plan 
Sample 1

Related to Collaborative Research Plan

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Plan As defined in Section 3.2(a).

Time is Money Join Law Insider Premium to draft better contracts faster.